Cargando…
Alemtuzumab: evidence for its potential in relapsing—remitting multiple sclerosis
Alemtuzumab (previously known as Campath(®)) is a humanized monoclonal antibody directed against the CD52 antigen on mature lymphocytes that results in lymphopenia and subsequent modification of the immune repertoire. Here we explore evidence for its efficacy and safety in relapsing–remitting multip...
| Autores principales: | , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Dove Medical Press
2013
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3593763/ https://www.ncbi.nlm.nih.gov/pubmed/23494602 http://dx.doi.org/10.2147/DDDT.S32687 |